4SC expands domatinostat combo testing
The Netherlands Cancer Institute (NKI) has joined 4SC AG as a partner in conducting a multicentre study of dominatostat/checkpoint blocker combos in treatment-native melanoma patients.
The Netherlands Cancer Institute (NKI) has joined 4SC AG as a partner in conducting a multicentre study of dominatostat/checkpoint blocker combos in treatment-native melanoma patients.
British start-up company Mogrify Ltd (Cambridge, UK) has added US$16m from a Series A round to its US$3.7m seed financing in February 2019. Existing investor Ahren Innovation Capital led the round, with Parkwalk, 24Haymarket, and the University of Bristol Enterprise Fund III participating.
A new test based on tumour organoids can predict how patients with advanced colorectal cancer (CRC) respond to chemotherapy treatment.
ADC Therapeutics SA has entered a R&D pact with Affimer developer Avacta Group plc aimed at creating and licencing Affimer-drug conjugates.
Licencing bluebird bio’s Inc know-how and technology in one-time gene therapies Novo Nordisk A/S tries to get foothold in the emerging hemophilia A gene therapy market.
Evotec SE has expanded its drug discovery customer base with US women’s health specialist Celmatix Inc.
German researchers have unraveled the mechanism of a ADEPs, a novel class of antibiotics, allowing pharmacological optimisation.
A new method allows real-time-visualisation of how the HI virus spreads between living T helper cells and which molecules it requires for this purpose.
Rottapharm Biotech (Monza, Italy) has published detailed results from a clinical Phase II trial of CR4056 in chronic pain from knee osteoarthritis.
Swiss drug discovery analytics specialist Creoptix AG has raised CHF8m in a Series C financing for commercial expansion.